Bayer announces more changes at the top
pharmafile | June 6, 2014 | News story | Manufacturing and Production, Research and Development, Sales and Marketing | Bayer, Dieter Weinand, Otsuka, dekkers, healthcare
US-based president at Japanese drugmaker Otsuka, Dieter Weinand, is to join Bayer Healthcare Pharmaceuticals as the new head of its prescription drugs unit.
The news follows major changes occurring at the German pharma giant, notably chief executive of Bayer group Marijn Dekkers and his decision to step down at the end of 2016, but also confirmation that Andrea Fibig, the current president of its Bayer Healthcare division, is to leave to become chief executive of International Flavors & Fragrances (IFF).
Olivier Brandicourt who is chief executive of Bayer’s HealthCare pharma unit, says: “We welcome Dieter Weinand to our management team. Based on his extensive commercial experience in the pharmaceutical industry, Dieter Weinand will drive the growth of our pharmaceutical business further and maximize the value of our product portfolio.”
Weinand has more than 25 years of experience in various commercial operative and strategic executive roles in pharma. He has been responsible for different markets according to the firm, such as Asia-Pacific, Europe, Middle East, Africa, Latin America and the US.
Prior to taking up his role, German-born Weinand has worked at companies including Pfizer and Bristol-Myers Squibb on the marketing of products in different therapeutic areas: such as cardiology, oncology, pulmonology, dermatology, immunology and inflammation.
Bayer now has over two years to decide who will succeed Dekkers in the top job for the group, but for the time being Werner Baumann will take on the role of chief strategy and portfolio officer, to “ensure continuity in key aspects of Bayer’s future development”.
Replacing Baumann as chief financial officer will be Johannes Dietsch, who is based in Shanghai and will assume Bayer’s CFO role there in China.
Brett Wells
Related Content
Bayer and Aignostics to collaborate for AI oncology research
Bayer and Aignostics have announced that they have entered into a strategic collaboration for several …
Bayer’s cardiovascular drug shows impressive Phase III results
Bayer’s finerenone drug has been shown to significantly reduce cardiovascular death or other cardiovascular events …
Bayer’s venous thromboembolism drug Xarelto gets UK approval for children
Bayer has received UK approval for the use of its oral Factor Xa inhibitor Xarelto …
